News &
Events
Corporate
Overview
Science &
Technology
R & D
Pipeline
Partnering
Investor
Relations
Media
Bond Restructuring
Novel vaccines for chronic disease treatment and prevention
Cytos Biotechnology is dedicated to the discovery, development and commercialization
of a novel class of medicines – called Immunodrugs™. Immunodrugs™ are therapeutic
vaccines intended for use in the treatment and prevention of common chronic diseases
which afflict millions of people worldwide.
2011, December 12:
Cytos Biotechnology obtains additional votes to validly pass the convertible bond restructuring proposal. Going concern of Cytos thereby ensured subject to final approval of the bond restructuring proposal by the relevant courts.
2011, November 10:
Today’s bondholders’ meeting of Cytos Biotechnology Ltd did not obtain sufficient votes to validly pass the convertible bond restructuring proposal. Cytos will try to obtain further votes from those bondholders who did not cast their vote.
2011, November 10:
Cytos Biotechnology Ltd holds a Bondholders’ meeting today. Trading of Cytos shares and convertible bonds temporarily suspended.
